ArticleAnnals of clinical microbiology and antimicrobials2026
Transient AdeABC-mediated eravacycline resistance in carbapenem-resistant Acinetobacter baumannii ST2: a mutation-independent efflux pump adaptation.
Article in Annals of clinical microbiology and antimicrobials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Eravacycline as a Novel Option for Treating Multidrug-Resistant Gram-Negative and Gram-Positive Bacterial Infections: A Narrative Review.Journal of clinical medicine · 2026Review
- Current State of the Fight Against Antimicrobial Resistance: What Are the Different Strategies for Tomorrow?Antibiotics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThis study evaluated the impact of sub-MIC eravacycline exposure on carbapenem-resistant Acinetobacter baumannii with tigecycline MIC ≥ 8 µg/mL in clinical laboratory testing, and analyzed the resistance mechanisms.
methods2144 A. baumannii isolates (2021–2024) from a Chinese tertiary hospital were analyzed for resistance trends. For 43 strains with tigecycline MIC ≥ 8 µg/mL, we conducted: (i) in vitro induction of resistance via serial sub-MIC eravacycline passage, (ii) efflux pump inhibition assays using phenylalanine-arginine β-naphthylamide, (iii) quantification of efflux pump gene expression (adeB, adeS), (iv) genomic analysis of resistance-associated mutations.
resultsEravacycline exhibited MIC50/90 values that were 2-4-fold lower than those of tigecycline, demonstrating superior in vitro efficacy. Exposure to sub-MIC levels of eravacycline significantly increased resistance to eravacycline, tigecycline, minocycline, and polymyxin B, with PAβN reversing these effects. The expression of efflux pump-related genes adeB and adeS was upregulated, especially in eravacycline-induced strains. Although 88.37% of strains lacked mutations, eravacycline resistance demonstrated greater stability in adeB or adeS mutants. In 97.06% of strains with tigecycline MIC ≥ 4 µg/mL, the induced eravacycline MICs exceeded achievable alveolar concentrations. Eravacycline resistance demonstrated a correlation with tigecycline. And its combination with polymyxin B showed no synergistic effect.
conclusionEravacycline exhibited superior in vitro antibacterial efficacy against A. baumannii compared to tigecycline, but it is necessary to be alert to the resistance caused by the rapid increase in efflux pump expression. These findings highlight the need for cautious clinical use of eravacycline to mitigate resistance development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.